- Email: [email protected]
26
JO U R N A L OF GE RI A TR IC O N C OLOG Y 3 ( 20 1 2 ) S 1 – S9
S5
the Catholic College of Higher Education of Leuven in 2002. In 2005 she finished her Masters in Nursing Science at the Catholic University of Leuven, and in 2007 she finished her Academic Teacher Education. She completed successfully the 1st Masterclass in Oncology Nursing in Malta in 2007 and a postgraduate in Geriatric Nursing in 2009. She has several years of working experience in the field of Geriatric Oncology and coordinates currently a large Geriatric Oncology study running in Belgium. She regularly gives national and international lectures in which she shares her expertise to improve the quality of care to older cancer patients.
portfolio of clinical trials with a particular emphasis on understanding response and resistance to systemic therapies and intratumour heterogeneity. His team collaborates closely with basic scientists such as Richard Marais and Charles Swanton and aims rapidly to translate laboratory advances into clinical trials testing rational therapeutic hypotheses. In 2012 Dr. Larkin has been appointed Chair of the UK NCRI Renal Clinical Studies Group and at the invitation of Sian James MP he also Chairs the a national Expert Group of the Melanoma Taskforce which has recently produced a report ‘Quality in Melanoma Care: A Best Practice Pathway’.
doi:10.1016/j.jgo.2012.09.127
doi:10.1016/j.jgo.2012.09.130
Heidi Klepin Internal Medicine, Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA Dr. Heidi D. Klepin is a dually trained geriatrician and oncologist with a clinical and research focus on geriatric oncology. She completed residency training in Internal Medicine, as well as fellowships in Geriatrics and Hematology/Oncology at Wake Forest University. She completed additional research training through a Masters program in Health Sciences Research. Using acute myelogenous leukemia (AML) as the model, she has designed research studies to begin to investigate the following themes among older cancer patients: 1) physical function as a predictor of treatment outcomes; 2) the impact of chemotherapy on physical function; and 3) interventions to minimize treatmentassociated physical disability. Past funding has included a T. Franklin Williams career development award through the American Society of Hematology investigating geriatric assessment (GA) pre and post chemotherapy among older adults receiving chemotherapy for AML. Her current research study supported by a Beeson K23 award investigates the feasibility and beneficial impact of an inpatient exercise program on physical function and quality of life during induction therapy for older adults with AML. Dr. Klepin participates in multiinstitutional research through collaborations in the Alliance Cooperative Group and the Cancer and Aging Research Group.
Katrina Lavelle School of Nursing, Midwifery & Social Work, The University of Manchester, Manchester, UK Dr. Katrina Lavelle is a Research Fellow at the School of Nursing, Midwifery and Social Work (University of Manchester, UK) specialising in cancer epidemiology. Her PhD demonstrated substantial differences in the treatment of older women with breast cancer, compared to younger postmenopausal women in the UK, which could not be explained by differences in tumour characteristics or health status. She has since held a National Institute of Health Research Post Doctoral Fellowship and is Principal Investigator of a Breast Cancer Campaign study investigating the role of patient choice in surgical treatment decisions for older breast cancer patients. She is also a Co-Investigator on a National Institute of Health Research Programme Grant for Applied Research which aims to individualise breast cancer treatment for older breast cancer patients to improve survival and minimise complications.
doi:10.1016/j.jgo.2012.09.128
Siri Rostoft Kristjansson Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway Siri Rostoft Kristjansson, MD, PhD is a resident at the Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway. She is completing her specialist training in internal medicine and geriatric medicine. Her thesis from 2011 presented data regarding comprehensive geriatric assessment and frailty measurements in the pre-operative evaluation of older patients with colorectal cancer. Her main research interest is within geriatric oncology, more specifically geriatric assessment, frailty indicators, and the application of these measures into clinical practice. doi:10.1016/j.jgo.2012.09.129
James Larkin The Royal Marsden Hospital, London, UK James Larkin FRCP PhD is a Medical Oncologist at the Royal Marsden NHS Foundation Trust. He was appointed a Consultant in 2008, having trained on the Marsden rotation, including a period spent as a Medical Research Council Training Fellow at the Institute of Cancer Research leading to the award of a PhD in 2005. He specialises in the treatment of melanoma and kidney cancer and leads a research team that runs a
doi:10.1016/j.jgo.2012.09.131
Stuart M. Lichtman 65+ Clinical Geriatrics Program, Memorial Hospital for Cancer and Allied Disease, USA Memorial Sloan-Kettering Cancer Center, Weill-Cornell Medical College, USA For the past 25 years Stuart M. Lichtman has been actively involved in the treatment of older patients with cancer. He has been an active participant in a number of research organizations, including the Cancer and Leukemia Group B (CALGB) Committee on Pharmacology & Experimental Therapeutics and their Committee on Cancer in the Elderly; the Scientific Advisory Board of the Geriatric Oncology Consortium; the International Society of Geriatric Oncology (SIOG) and its Taskforces on Geriatric Assessment, Renal Dysfunction, Chemotherapy and Gynecologic Oncology and currently on the Board of Directors; and the Elderly Taskforce of the Gynecologic Oncology Group. He was on the Program Committee for the 2005 and 2006 meetings of American Society of Clinical Oncology (ASCO) and led the Patient Care Tract and have been reappointed for 2012-2014 as well as the ASCO Special Interest Group in Geriatric Oncology. In 2008 and 2010 he was a faculty member of the ASCO Educational Session devoted to the pharmacology of chemotherapy and assessment in older patients. He has been a faculty member for the Vail ASCO/AACR Clinical Trials Workshop (2004-2009) and was the Scientific Chair of the 11th International Society of Geriatric Oncology (SIOG) meeting in 2011. doi:10.1016/j.jgo.2012.09.132
Massimo Maffezzini Dr. Massimo Maffezzini was born in Morbegno (Sondrio) in the northern part of Italy on July, 17, 1955. He graduated in Medicine, with full marks, in June 1980, at the Università degli Studi di Pavia, Italy. He completed Residency in Urology
S5
the Catholic College of Higher Education of Leuven in 2002. In 2005 she finished her Masters in Nursing Science at the Catholic University of Leuven, and in 2007 she finished her Academic Teacher Education. She completed successfully the 1st Masterclass in Oncology Nursing in Malta in 2007 and a postgraduate in Geriatric Nursing in 2009. She has several years of working experience in the field of Geriatric Oncology and coordinates currently a large Geriatric Oncology study running in Belgium. She regularly gives national and international lectures in which she shares her expertise to improve the quality of care to older cancer patients.
portfolio of clinical trials with a particular emphasis on understanding response and resistance to systemic therapies and intratumour heterogeneity. His team collaborates closely with basic scientists such as Richard Marais and Charles Swanton and aims rapidly to translate laboratory advances into clinical trials testing rational therapeutic hypotheses. In 2012 Dr. Larkin has been appointed Chair of the UK NCRI Renal Clinical Studies Group and at the invitation of Sian James MP he also Chairs the a national Expert Group of the Melanoma Taskforce which has recently produced a report ‘Quality in Melanoma Care: A Best Practice Pathway’.
doi:10.1016/j.jgo.2012.09.127
doi:10.1016/j.jgo.2012.09.130
Heidi Klepin Internal Medicine, Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA Dr. Heidi D. Klepin is a dually trained geriatrician and oncologist with a clinical and research focus on geriatric oncology. She completed residency training in Internal Medicine, as well as fellowships in Geriatrics and Hematology/Oncology at Wake Forest University. She completed additional research training through a Masters program in Health Sciences Research. Using acute myelogenous leukemia (AML) as the model, she has designed research studies to begin to investigate the following themes among older cancer patients: 1) physical function as a predictor of treatment outcomes; 2) the impact of chemotherapy on physical function; and 3) interventions to minimize treatmentassociated physical disability. Past funding has included a T. Franklin Williams career development award through the American Society of Hematology investigating geriatric assessment (GA) pre and post chemotherapy among older adults receiving chemotherapy for AML. Her current research study supported by a Beeson K23 award investigates the feasibility and beneficial impact of an inpatient exercise program on physical function and quality of life during induction therapy for older adults with AML. Dr. Klepin participates in multiinstitutional research through collaborations in the Alliance Cooperative Group and the Cancer and Aging Research Group.
Katrina Lavelle School of Nursing, Midwifery & Social Work, The University of Manchester, Manchester, UK Dr. Katrina Lavelle is a Research Fellow at the School of Nursing, Midwifery and Social Work (University of Manchester, UK) specialising in cancer epidemiology. Her PhD demonstrated substantial differences in the treatment of older women with breast cancer, compared to younger postmenopausal women in the UK, which could not be explained by differences in tumour characteristics or health status. She has since held a National Institute of Health Research Post Doctoral Fellowship and is Principal Investigator of a Breast Cancer Campaign study investigating the role of patient choice in surgical treatment decisions for older breast cancer patients. She is also a Co-Investigator on a National Institute of Health Research Programme Grant for Applied Research which aims to individualise breast cancer treatment for older breast cancer patients to improve survival and minimise complications.
doi:10.1016/j.jgo.2012.09.128
Siri Rostoft Kristjansson Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway Siri Rostoft Kristjansson, MD, PhD is a resident at the Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway. She is completing her specialist training in internal medicine and geriatric medicine. Her thesis from 2011 presented data regarding comprehensive geriatric assessment and frailty measurements in the pre-operative evaluation of older patients with colorectal cancer. Her main research interest is within geriatric oncology, more specifically geriatric assessment, frailty indicators, and the application of these measures into clinical practice. doi:10.1016/j.jgo.2012.09.129
James Larkin The Royal Marsden Hospital, London, UK James Larkin FRCP PhD is a Medical Oncologist at the Royal Marsden NHS Foundation Trust. He was appointed a Consultant in 2008, having trained on the Marsden rotation, including a period spent as a Medical Research Council Training Fellow at the Institute of Cancer Research leading to the award of a PhD in 2005. He specialises in the treatment of melanoma and kidney cancer and leads a research team that runs a
doi:10.1016/j.jgo.2012.09.131
Stuart M. Lichtman 65+ Clinical Geriatrics Program, Memorial Hospital for Cancer and Allied Disease, USA Memorial Sloan-Kettering Cancer Center, Weill-Cornell Medical College, USA For the past 25 years Stuart M. Lichtman has been actively involved in the treatment of older patients with cancer. He has been an active participant in a number of research organizations, including the Cancer and Leukemia Group B (CALGB) Committee on Pharmacology & Experimental Therapeutics and their Committee on Cancer in the Elderly; the Scientific Advisory Board of the Geriatric Oncology Consortium; the International Society of Geriatric Oncology (SIOG) and its Taskforces on Geriatric Assessment, Renal Dysfunction, Chemotherapy and Gynecologic Oncology and currently on the Board of Directors; and the Elderly Taskforce of the Gynecologic Oncology Group. He was on the Program Committee for the 2005 and 2006 meetings of American Society of Clinical Oncology (ASCO) and led the Patient Care Tract and have been reappointed for 2012-2014 as well as the ASCO Special Interest Group in Geriatric Oncology. In 2008 and 2010 he was a faculty member of the ASCO Educational Session devoted to the pharmacology of chemotherapy and assessment in older patients. He has been a faculty member for the Vail ASCO/AACR Clinical Trials Workshop (2004-2009) and was the Scientific Chair of the 11th International Society of Geriatric Oncology (SIOG) meeting in 2011. doi:10.1016/j.jgo.2012.09.132
Massimo Maffezzini Dr. Massimo Maffezzini was born in Morbegno (Sondrio) in the northern part of Italy on July, 17, 1955. He graduated in Medicine, with full marks, in June 1980, at the Università degli Studi di Pavia, Italy. He completed Residency in Urology